Colin K. Skepper,Duncan Armstrong,Carl J. Balibar,Daniel Bauer,Cornelia Bellamacina,Bret M. Benton,Dirksen Bussiere,Gianfranco De Pascale,Javier De Vicente,Charles R. Dean,Bhavesh Dhumale,L. Mark Fisher,John Fuller,Mangesh Fulsunder,Lauren M. Holder,Cheng Hu,Bhavin Kantariya,Guillaume Lapointe,Jennifer A. Leeds,Xiaolin Li,Peichao Lu,Anatoli Lvov,Sylvia Ma,Shravanthi Madhavan,Swapnil Malekar,David McKenney,Wosenu Mergo,Louis Metzger,Heinz E. Moser,Daniel Mutnick,Jonas Noeske,Colin Osborne,Ashish Patel,Darshit Patel,Tushar Patel,Krunal Prajapati,Katherine R. Prosen,Folkert Reck,Daryl L. Richie,Alice Rico,Mark R. Sanderson,Shailesh Satasia,William S. Sawyer,Jogitha Selvarajah,Nirav Shah,Kartik Shanghavi,Wei Shu,Katherine V. Thompson,Martin Traebert,Anand Vala,Lakhan Vala,Dennis A. Veselkov,Jason Vo,Michael Wang,Marcella Widya,Sarah L. Williams,Yongjin Xu,Qin Yue,Richard Zang,Bo Zhou,Alexey Rivkin

Abstract:Since their discovery over 5 decades ago, quinolone antibiotics have found enormous success as broad spectrum agents that exert their activity through dual inhibition of bacterial DNA gyrase and topoisomerase IV. Increasing rates of resistance, driven largely by target-based mutations in the GyrA/ParC quinolone resistance determining region, have eroded the utility and threaten the future use of this vital class of antibiotics. Herein we describe the discovery and optimization of a series of 4-(aminomethyl)quinolin-2(1H)-ones, exemplified by 34, that inhibit bacterial DNA gyrase and topoisomerase IV and display potent activity against ciprofloxacin-resistant Gram-negative pathogens. X-ray crystallography reveals that 34 occupies the classical quinolone binding site in the topoisomerase IV-DNA cleavage complex but does not form significant contacts with residues in the quinolone resistance determining region.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00347?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00347</a>.Crystallographic data table for the structure of K. pneumoniae topoisomerase IV bound to compound 34; unbiased electron-density difference map (Fobs – Fcalc) for 34 bound to K. pneumoniae topoisomerase IV; interaction diagram of compound 34 bound to topoisomerase IV from K. pneumoniae; plot of CFU/thigh determined for each dose of compound 34 in the neutropenic murine thigh infection model; SEC chromatograms showing separation of supercoiled and relaxed DNA and detection of decatenated kDNA; LC/MS traces of all final compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00347/suppl_file/jm0c00347_si_001.pdf">PDF</a>)Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00347/suppl_file/jm0c00347_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

The Structural Features of Novel Bacterial Topoisomerase Inhibitors That Define Their Activity on Topoisomerase IV

Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria

Novel Potentially Antibacterial Naphthalimide-Derived Metronidazoles: Design, Synthesis, Biological Evaluation and Supramolecular Interactions with DNA, Human Serum Albumin and Topoisomerase II

Discovery of novel bacterial topoisomerase I inhibitors by use of in silico docking and in vitro assays

Multi-Targeting Exploration of New 2-Aminothiazolyl Quinolones: Synthesis, Antimicrobial Evaluation, Interaction with Dna, Combination with Topoisomerase Iv and Penetrability into Cells

Discovery of aminopiperidine based potent & novel topoisomerase inhibitor with broad spectrum anti-bacterial activity

Recent developments of topoisomerase inhibitors: Clinical trials, emerging indications, novel molecules and global sales

Dynamic Profiling and Binding Affinity Prediction of NBTI Antibacterials against DNA Gyrase Enzyme by Multidimensional Machine Learning and Molecular Dynamics Simulations

Topoisomerase I inhibitors: Challenges, progress and the road ahead

Target-Based Resistance in Pseudomonas Aeruginosa and Escherichia Coli to Nbti 5463, A Novel Bacterial Type Ii Topoisomerase Inhibitor

Development of narrow-spectrum topoisomerase-targeting antibacterials against mycobacteria

Structure-activity relationships of aminocoumarin-type gyrase and topoisomerase IV inhibitors obtained by combinatorial biosynthesis.

Dual targeting DNA gyrase B (GyrB) and topoisomerse IV (ParE) inhibitors: A review

Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-pyridone Type II DNA Topoisomerase Inhibitors Active Against Multidrug Resistant Gram-negative Bacteria

Emerging DNA topoisomerase inhibitors as anticancer drugs

Topoisomerase Inhibitors Addressing Fluoroquinolone Resistance in Gram-Negative Bacteria

Evolutionary Trace Analysis of Eukaryotic DNA Topoisomerase I Superfamily: Identification of Novel Antitumor Drug Binding Site

Discovery of Novel Topoisomerase II Inhibitors by Medicinal Chemistry Approaches

Crystal Structures, Molecular Docking and In Vitro Investigations of Two 4-Substituted 2-(5,5-dimethyl-3-styrylcyclohex-2-enylidene)malononitrile Derivatives as Potential Topoisomerase II Inhibitors

Discovery Of Dna Topoisomerase I Inhibitors With Low-Cytotoxicity Based On Virtual Screening From Natural Products

New Strategies in the Discovery of Novel Non-Camptothecin Topoisomerase I Inhibitors